Neuroscience is experiencing a resurgence in biopharmaceutical investment, exemplified by Draig Therapeutics' $140 million Series A financing led by Access Biotechnology and other investors. Founded on Cardiff University research, Draig is developing oral neuropsychiatry therapies targeting glutamate/GABA pathways to address major depressive disorder with differentiated profiles lacking ketamine-like side effects. This revitalization follows a period of diminished industry focus and aligns with broader trends of renewed interest after landmark acquisitions such as Bristol Myers Squibb's purchase of Karuna Therapeutics. Draig's progress signals a promising new wave in central nervous system disorder therapeutics.